CLIR

CLIR enhances interpretation of newborn screening data for lysosomal storage disorders by applying bioinformatics-based post-analytical interpretive algorithms to improve diagnostic accuracy across multiple screening platforms.

Key Features:

• Integration with high-throughput screening assays: Operates on residual newborn dried blood spot specimens screened simultaneously for Fabry disease, Gaucher disease, mucopolysaccharidosis type I, and Pompe disease.
• Prospective comparative effectiveness evaluation: Was evaluated in a prospective study of nearly 100,000 samples across tandem mass spectrometry, digital microfluidics, and immunocapture technology-based multiplex assays.
• Post-analytical interpretation enhancement: Provides advanced post-analytical interpretive tools that improve result interpretation beyond analyte-specific reference ranges and cutoffs.
• Reduction in second-tier testing: Decreases the need for second-tier enzyme assays by 66% to 95%.
• Improved diagnostic accuracy: When combined with disease-specific biochemical second-tier tests, yields the lowest false positive rates and highest positive predictive values across tested platforms.

Scientific Applications:

• Newborn screening for lysosomal storage disorders: Enhances early detection of Fabry, Gaucher, mucopolysaccharidosis type I, and Pompe disease through integrated analysis of screening data.
• Triage and follow-up reduction: Refines positive screens to reduce unnecessary second-tier testing and associated resource use.
• Population screening program improvement: Improves positive predictive value and lowers false positives across tandem mass spectrometry, digital microfluidics, and immunocapture multiplex platforms in public health settings.

Methodology:

Applies bioinformatics algorithms and advanced post-analytical interpretive tools to analyze newborn screening results and integrates disease-specific biochemical second-tier test results for interpretation.